BMC Microbiology (Sep 2022)

Neutralization of the Staphylococcus aureus Panton-Valentine leukocidin by African and Caucasian sera

  • Tobias Grebe,
  • Viktoria Rudolf,
  • Christiane Sidonie Gouleu,
  • Bettina Löffler,
  • Ayola Akim Adegnika,
  • Adebayo Osagie Shittu,
  • Stefanie Deinhardt-Emmer,
  • Silke Niemann,
  • Frieder Schaumburg

DOI
https://doi.org/10.1186/s12866-022-02636-5
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background The prevalence of Staphylococcus aureus isolates carrying the Panton-Valentine leukocidin (PVL) gene is higher in Africa (≈50%) compared to Europe (< 5%). The study aimed to measure anti-PVL-antibodies in Africans and Germans in a multi-center study and to test whether detected antibodies can neutralize the cytotoxic effect of PVL on polymorphonuclear leukocytes (PMNs). Methods Sera from asymptomatic Africans (n = 22, Nigeria, Gabon) and Caucasians (n = 22, Germany) were used to quantify antibody titers against PVL and α-hemolysin (in arbitrary units [AU]) by ELISA. PMNs from one African and German donor were exposed to 5 nM recombinant PVL to measure the neutralizing effect of serial dilutions of pooled sera from African and Caucasian participants, or donor sera at 0.625 and 2.5% (v/v). Results Anti-PVL-antibodies were significantly higher in Africans than in Germans (1.9 vs. 0.7 AU, p < 0.0001). The pooled sera from the study participants neutralized the cytotoxic effect of PVL on African and German PMNs in a dose dependent manner. Also, neutralization of PVL on PMNs from the African and German donors had a stronger effect with African sera (half-maximal inhibitory concentration (IC50) = 0.27 and 0.47%, respectively) compared to Caucasian sera (IC50 = 3.51 and 3.59% respectively). Conclusion Africans have higher levels of neutralizing anti-PVL-antibodies. It remains unclear if or at what level these antibodies protect against PVL-related diseases.

Keywords